John Maxwell

John, Senior Vice President of Chemistry, has more than 20 years of experience in the drug discovery industry. He spent 15 years at Vertex Pharmaceuticals in roles of increasing responsibility, managing departmental training and discussion programs, leading the global corporate “people and culture” working group, as well as cross-site projects. At Vertex he and his teams delivered six clinical candidates across HCV, oncology, and respiratory disease programs. As a member of the global hit ID team, he oversaw numerous hit finding and hit triage campaigns which provided a solid foundation for tackling the new oncology targets at Tango Therapeutics. At Tango, John has led the building of the drug discovery organization and served as project leader for the flagship MTA-cooperative PRMT5 inhibitor program.

John received his doctorate in chemistry from Johns Hopkins University and obtained a Bachelor of Science in chemistry from St. Joseph’s University.

John received his doctorate in chemistry from Johns Hopkins University and obtained a Bachelor of Science in chemistry from St. Joseph’s University.